Novocure Announces Presentations On Tumor Treating Fields Therapy, Including New Clinical Data And Real-World Evidence, At 2023 Society For Neuro-Oncology Annual Meeting
Novocure (NASDAQ:NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma